Headlines about Gemphire Therapeutics (NASDAQ:GEMP) have trended somewhat positive on Wednesday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.6889363242949 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Gemphire Therapeutics (NASDAQ GEMP) opened at $7.86 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17. Gemphire Therapeutics has a fifty-two week low of $7.20 and a fifty-two week high of $21.59.

Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.14). equities analysts predict that Gemphire Therapeutics will post -3.31 EPS for the current year.

A number of brokerages have recently issued reports on GEMP. Zacks Investment Research upgraded Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Thursday, November 16th. Canaccord Genuity reiterated a “buy” rating and set a $31.00 target price on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. Piper Jaffray Companies reiterated an “overweight” rating and set a $22.00 target price on shares of Gemphire Therapeutics in a research report on Friday, October 27th. HC Wainwright began coverage on Gemphire Therapeutics in a research report on Thursday, August 31st. They set a “buy” rating and a $21.00 target price on the stock. Finally, Roth Capital began coverage on Gemphire Therapeutics in a research report on Thursday, October 19th. They set a “buy” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.17.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-gemphire-therapeutics-gemp-stock-price/1774432.html.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Insider Buying and Selling by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.